课题基金 / 基金详情

REDOSING WITH CP-675,206 IN SUBJECTS WITH CLINICAL BENEFIT ENROLLED IN A PHAS

REDOSING WITH CP-675,206 IN SUBJECTS WITH CLINICAL BENEFIT ENROLLED IN A PHAS
在分阶段入组的受试者中重新服用 CP-675,206 可获得临床益处
批准号：
7606759
负责人：
ANTONI RIBAS
金额：
$0.1万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
项目状态：
已结题
起止时间：
2007-02-21 至 2007-11-30
来源：
https://reporter.nih.gov/project-details/7606759
关键词：
ClinicalComputer Retrieval of Information on Scientific Projects DatabaseEnrollmentFundingGrantInstitutionMonoclonal AntibodiesPatientsPrior TherapyResearchResearch PersonnelResourcesSourceUnited States National Institutes of Healthmelanomaresponse

项目摘要

项目成果

ANTONI RIBAS的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: To evaluate the immunological activity of bi-annual redosing of the CTLA-4 blocking monoclonal antibody CP-675,260 in patients with melanoma and response to prior therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 3: Modeling and overcoming resistance to melanoma immunotherapy
Project 3: Modeling and overcoming resistance to melanoma immunotherapy
Project 3: Modeling and overcoming resistance to melanoma immunotherapy
Administrative and Statistics Core